Chemical inhibitors of cyclin-dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells

International Journal of Developmental Neuroscience

Volumn 21, Issue 6, 2003, Pages 321-326

  Nguyen, Laurent ^a   Malgrange, Brigitte ^a   Rocher, Véronique ^a   Hans, Grégory ^a   Moonen, Gustave ^a,b   Rigo, Jean Michel ^a   Belachew, Shibeshih ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Apoptosis; Cell cycle; Differentiation; Oligodendroglia; Rat cerebral cortex; Roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GROWTH FACTOR; PURINE DERIVATIVE; ROSCOVITINE; THYROID HORMONE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERABILITY; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REMYELINIZATION; STEM CELL;

EID: 0041621478     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(03)00075-3     Document Type: Article

References (23)

1. Avellana-Adalid V., Nait-Oumesmar B., Lachapelle F., Baron-Van Evercooren A. Expansion of rat oligodendrocyte progenitors into proliferative "oligospheres" that retain differentiation potential. J. Neurosci. Res. 45:1996;558-570.
2. +-dependent transporters. Eur. J. Neurosci. 12:2000;1924-1930.
3. Belachew S., Aguirre A.A., Wang H., Vautier F., Yuan X., Anderson S., Kirby M., Gallo V. Cyclin-dependent kinase-2 controls oligodendrocyte progenitor cell cycle progression and is downregulated in adult oligodendrocyte progenitors. J. Neurosci. 22:2002;8553-8562.
4. Casaccia-Bonnefil P. Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia. 29:2000;124-135.
5. Durand B., Raff M. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays. 22:2000;64-71.
6. Edlund T., Jessell T.M. Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. Cell. 96:1999;211-224.
7. Ghiani C.A., Gallo V. Inhibition of cyclin E-cyclin-dependent kinase 2 complex formation and activity is associated with cell cycle arrest and withdrawal in oligodendrocyte progenitor cells. J. Neurosci. 21:2001;1274-1282.
8. Ghiani C.A., Eisen A.M., Yuan X., DePinho R.A., McBain C.J., Gallo V. Neurotransmitter receptor activation triggers p27(Kip1) and p21(CIP1) accumulation and G1 cell cycle arrest in oligodendrocyte progenitors. Development. 126:1999;1077-1090.
9. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
10. King K.L., Cidlowski J.A. Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60:1998;601-617.
11. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425.
12. Louis J.C., Magal E., Muir D., Manthorpe M., Varon S. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 31:1992;193-204.
13. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
14. Meijer L., Leclerc S., Leost M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 82:1999;279-284.
15. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 13:1997;261-291.
16. Park D.S., Farinelli S.E., Greene L.A. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271:1996;8161-8169.
17. Sausville E.A., Zaharevitz D., Gussio R., Meijer L., Louarn-Leost M., Kunick C., Schultz R., Lahusen T., Headlee D., Stinson S., Arbuck S.G., Senderowicz A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 82:1999;285-292.
18. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92:2000;376-387.
19. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
20. Shibata Y., Nishimura S., Okuyama A., Nakamura T. p53-Independent induction of apoptosis by cyclin-dependent kinase inhibition. Cell Growth Differ. 7:1996;887-891.
21. Shoshan Y., Nishiyama A., Chang A., Mork S., Barnett G.H., Cowell J.K., Trapp B.D., Staugaitis S.M. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10361-10366.
22. Yu C., Takeda M., Soliven B. Regulation of cell cycle proteins by TNF-alpha and TGF-beta in cells of oligodendroglial lineage. J. Neuroimmunol. 108:2000;2-10.
23. Zezula J., Casaccia-Bonnefil P., Ezhevsky S.A., Osterhout D.J., Levine J., Dowdy S.F., Chao M.V., Koff A. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2:2001;27-34.